<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898738</url>
  </required_header>
  <id_info>
    <org_study_id>2021p001294</org_study_id>
    <nct_id>NCT04898738</nct_id>
  </id_info>
  <brief_title>Prospective COVID-19 Cohort Study, Dominican Republic</brief_title>
  <official_title>Prospective COVID-19 Cohort Study to Assess the Epidemiology, Transmission and Control of SARS-CoV-2 in the Dominican Republic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Broad Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Salud Publica y Asistencia Social, Republica Dominicana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will build on an existing CDC funded cooperative agreement in the Dominican&#xD;
      Republic with the Brigham and Women's Hospital (2018-2023) that includes (i) prospective&#xD;
      COVID-19 and AFI surveillance at two health facilities and (ii) a nationally representative&#xD;
      cross-sectional community-based serological survey of approximately 7,000 healthy adults and&#xD;
      children targeting SARS-CoV-2 and other AFI pathogens to be conducted between April and June&#xD;
      2021. This linked study will establish a nested cohort of 2,000 participants enrolled in the&#xD;
      national serological survey and prospectively monitor them for COVID-19 symptoms, conduct&#xD;
      serial serological testing, implement molecular surveillance for SARS-CoV-2 and sequencing&#xD;
      for variants of concern, implement and evaluate WASH mitigation measures, and monitor uptake&#xD;
      and perceptions of COVID-19 vaccines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective cohort study that aims to prospectively monitor 2,000 community-based study participants with serial serological screening for SARS-CoV-2 and enhanced molecular surveillance for active infection. Nested within this cohort is a randomized trial that will allocate study participants into two arms: thoe that receive versus do not receive alcohol-based hand sanitizer (ABHS) through the course of the study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hand hygiene practices</measure>
    <time_frame>1 year</time_frame>
    <description>The average daily frequency of study participant hand hygiene events over the previous seven days will be assessed using standardized survey questionnaires at 0-, 3-, 6-, 9-, and 12-months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability of hand hygiene technology</measure>
    <time_frame>1 year</time_frame>
    <description>Study participants preference for different hand hygiene technology (e.g. soap and water, ABHR) as measured using a five-point Likert Scale at 0-, 3-, 6-, 9-, and 12-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-Cov-2 seroconversion</measure>
    <time_frame>1 year</time_frame>
    <description>Number of study participants that seroconvert from SARS-CoV-2 seronegative to seropositive at time points 0-, 6-, and 12-months as assessed by presence of anti-nucleocapsid immunoglobulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Alcohol-based hand sanitizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half the study households with receive ABHS through the course of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Alcohol-based hand sanitizer</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Half the study households with not receive ABHS through the course of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alcohol based hand sanitizer</intervention_name>
    <description>Provision of ABHS to randomly selected households</description>
    <arm_group_label>Alcohol-based hand sanitizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously enrolled in a linked national community-based seroepidemiological study in&#xD;
             the Dominican Republic&#xD;
&#xD;
          -  Agreed and consented to be recontacted to participate in additional research studies&#xD;
             at the time of enrollment in #1&#xD;
&#xD;
          -  â‰¥2 years of age&#xD;
&#xD;
          -  Agree to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ward of the State&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric J Nilles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric J Nilles, MD</last_name>
    <phone>7819957077</phone>
    <email>enilles@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Devan Dumas, MPH</last_name>
    <phone>4103749690</phone>
    <email>ddumas@bwh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Eric J. Nilles, M.D.,M.S.C.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hand Sanitizers</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data for epidemiological analyses and modelling (including demographic data, clinical data, and survey questionnaire survey) will be shared with the following collaborators: Adam Kucharski (LSHTM), Colleen Lau (University of Queensland), Marietta Vasquez (Yale University), Matt Lozier (US CDC), Pardis Sabeti (Broad Institute), and staff at the Health Ministry Division of Epidemiology. Non-identifiable data shared with listed collaborators will be performed with secure file transfer.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

